In the latest trading session, 0.52 million UroGen Pharma Ltd (NASDAQ:URGN) shares changed hands as the company’s beta touched 1.12. With the company’s most recent per share price at $12.35 changed hands at -$0.35 or -2.76% at last look, the market valuation stands at $520.06M. URGN’s current price is a discount, trading about -67.61% off its 52-week high of $20.70. The share price had its 52-week low at $10.60, which suggests the last value was 14.17% up since then. When we look at UroGen Pharma Ltd’s average trading volume, we note the 10-day average is 0.62 million shares, with the 3-month average coming to 480.90K.
Analysts gave the UroGen Pharma Ltd (URGN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.33. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended URGN as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
UroGen Pharma Ltd (NASDAQ:URGN) trade information
Instantly URGN was in red as seen in intraday trades today. With action -5.44%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -17.67%, with the 5-day performance at -5.44% in the red. However, in the 30-day time frame, UroGen Pharma Ltd (NASDAQ:URGN) is -11.21% down. Looking at the short shares, we see there were 6.37 million shares sold at short interest cover period of 12.04 days.
The consensus price target for the stock as assigned by Wall Street analysts is 43, meaning bulls need an upside of 71.28% from its recent market value. According to analyst projections, URGN’s forecast low is 22 with 60 as the target high. To hit the forecast high, the stock’s price needs a -385.83% plunge from its current level, while the stock would need to soar -78.14% for it to hit the projected low.
UroGen Pharma Ltd (URGN) estimates and forecasts
Data shows that the UroGen Pharma Ltd share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -12.35% over the past 6 months, a 1.69% in annual growth rate that is considerably lower than the industry average of 17.80%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 5.89%. The 2024 estimates are for UroGen Pharma Ltd earnings to increase by 2.16%.
URGN Dividends
UroGen Pharma Ltd is expected to release its next quarterly earnings report on 2024-Nov-12.
UroGen Pharma Ltd (NASDAQ:URGN)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 9.20% of UroGen Pharma Ltd shares while 93.39% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 102.85%. There are 93.39% institutions holding the UroGen Pharma Ltd stock share, with RTW INVESTMENTS, LP the top institutional holder. As of 2024-06-30, the company held 10.6572% of the shares, roughly 3.56 million URGN shares worth $59.69 million.
ADAGE CAPITAL PARTNERS GP, L.L.C. holds the second largest percentage of outstanding shares, with 9.8862% or 3.3 million shares worth $55.37 million as of 2024-06-30.
